News and Announcements
Global Drug Giant Merck is Investing in Australian Biopharmaceutical Bionomics
- Published October 09, 2015 2:36PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
8th October 2015, By Chris Pash, Business Insider
Global drug giant Merck & Co has made a strategic investment in an Australia biopharmaceutical company Bionomics, which works on the discovery and development of treatment for cancer and diseases of the central nervous system.
Merck, one of the largest pharmaceutical companies in the world, is buying 21,659,230 million shares at $0.5938, a 29% premium to Bionomics’ closing price on Wednesday, a total investment of about $12.8 million.
The news sent Bionomics shares more than 18% higher to $0.545.
To read the full story, please click here.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
